JP2016147893A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016147893A5 JP2016147893A5 JP2016060063A JP2016060063A JP2016147893A5 JP 2016147893 A5 JP2016147893 A5 JP 2016147893A5 JP 2016060063 A JP2016060063 A JP 2016060063A JP 2016060063 A JP2016060063 A JP 2016060063A JP 2016147893 A5 JP2016147893 A5 JP 2016147893A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- pharmaceutical composition
- group
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 125000001188 haloalkyl group Chemical group 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 15
- 125000004438 haloalkoxy group Chemical group 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- -1 N-pyrrolidinyl Chemical group 0.000 claims 6
- 206010002022 amyloidosis Diseases 0.000 claims 6
- 150000001540 azides Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- JUWDSDKJBMFLHE-UHFFFAOYSA-N 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone Chemical compound CC=1N(C=2C=CC(F)=CC=2)C(C)=CC=1C(=O)CN1CCCC1 JUWDSDKJBMFLHE-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- 150000001408 amides Chemical group 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 208000023769 AA amyloidosis Diseases 0.000 claims 1
- 208000023761 AL amyloidosis Diseases 0.000 claims 1
- 208000022385 ALys amyloidosis Diseases 0.000 claims 1
- 208000011403 Alexander disease Diseases 0.000 claims 1
- 102100034452 Alternative prion protein Human genes 0.000 claims 1
- 206010001881 Alveolar proteinosis Diseases 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 208000009575 Angelman syndrome Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 208000010482 CADASIL Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims 1
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010010996 Corneal degeneration Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 206010011659 Cutaneous amyloidosis Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010064553 Dialysis amyloidosis Diseases 0.000 claims 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 1
- 206010016202 Familial Amyloidosis Diseases 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 201000004176 Gelatinous drop-like corneal dystrophy Diseases 0.000 claims 1
- 208000009119 Giant Axonal Neuropathy Diseases 0.000 claims 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims 1
- 102000010445 Lactoferrin Human genes 0.000 claims 1
- 108010063045 Lactoferrin Proteins 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007871 Odontogenic Tumors Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 102000008847 Serpin Human genes 0.000 claims 1
- 108050000761 Serpin Proteins 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 208000016738 bone Paget disease Diseases 0.000 claims 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 201000006061 fatal familial insomnia Diseases 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 210000003000 inclusion body Anatomy 0.000 claims 1
- 206010023497 kuru Diseases 0.000 claims 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 1
- 229940078795 lactoferrin Drugs 0.000 claims 1
- 235000021242 lactoferrin Nutrition 0.000 claims 1
- 208000015413 lichen amyloidosis Diseases 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- 208000027825 odontogenic neoplasm Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003994 retinal ganglion cell Anatomy 0.000 claims 1
- 239000003001 serine protease inhibitor Substances 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 1
- 208000027121 wild type ATTR amyloidosis Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33695910P | 2010-01-28 | 2010-01-28 | |
| US61/336,959 | 2010-01-28 | ||
| US37340410P | 2010-08-13 | 2010-08-13 | |
| US61/373,404 | 2010-08-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551323A Division JP2013518129A (ja) | 2010-01-28 | 2011-01-28 | プロテアソーム活性を向上させるための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016147893A JP2016147893A (ja) | 2016-08-18 |
| JP2016147893A5 true JP2016147893A5 (OSRAM) | 2016-12-15 |
| JP6371786B2 JP6371786B2 (ja) | 2018-08-08 |
Family
ID=44320152
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551323A Pending JP2013518129A (ja) | 2010-01-28 | 2011-01-28 | プロテアソーム活性を向上させるための組成物および方法 |
| JP2016060063A Expired - Fee Related JP6371786B2 (ja) | 2010-01-28 | 2016-03-24 | プロテアソーム活性を向上させるための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551323A Pending JP2013518129A (ja) | 2010-01-28 | 2011-01-28 | プロテアソーム活性を向上させるための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20130045992A1 (OSRAM) |
| EP (1) | EP2528911B1 (OSRAM) |
| JP (2) | JP2013518129A (OSRAM) |
| KR (1) | KR20120117905A (OSRAM) |
| CN (1) | CN102844313B (OSRAM) |
| AU (1) | AU2011210765A1 (OSRAM) |
| BR (1) | BR112012018631A8 (OSRAM) |
| CA (1) | CA2787785C (OSRAM) |
| MX (1) | MX336731B (OSRAM) |
| RU (1) | RU2012136451A (OSRAM) |
| SG (1) | SG182662A1 (OSRAM) |
| WO (1) | WO2011094545A2 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120117905A (ko) | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| WO2012012712A2 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Tricyclic proteasome activity enhancing compounds |
| PT2707101T (pt) | 2011-05-12 | 2019-05-30 | Proteostasis Therapeutics Inc | Reguladores da proteostase |
| WO2013039438A1 (en) * | 2011-09-16 | 2013-03-21 | Vivolux Ab | Proteasome deubiquinating inhibitor screening |
| CA2861464C (en) | 2012-01-25 | 2018-03-06 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating tricyclic compounds |
| US9802904B2 (en) | 2012-12-28 | 2017-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof |
| WO2014116228A1 (en) * | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
| US10563225B2 (en) * | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| UA121309C2 (uk) | 2014-02-03 | 2020-05-12 | Вітае Фармасьютікалс, Ллс | Дигідропіролопіридинові інгібітори ror-гамма |
| CN104844704B (zh) * | 2014-02-17 | 2018-02-23 | 华东师范大学 | Ub‑Nanoluc、Ub‑Ub‑GS‑Nanoluc报告基因系统及其构建和应用 |
| BR112017007460A2 (pt) | 2014-10-14 | 2017-12-19 | Vitae Pharmaceuticals Inc | inibidores de di-hidropirrolopiridina de ror-gama |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| CN104478780B (zh) * | 2014-11-17 | 2017-04-19 | 华东师范大学 | 酰基吡咯类小分子有机化合物及其衍生物、用途及其制备方法 |
| ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| MX385332B (es) | 2015-11-20 | 2025-03-18 | Vitae Pharmaceuticals Llc | Moduladores de ror-gamma. |
| GB201521109D0 (en) * | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| US20190016680A1 (en) | 2016-01-14 | 2019-01-17 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| CN106065389A (zh) * | 2016-08-08 | 2016-11-02 | 山东理工大学 | 一种促进木瓜蛋白酶活性的方法及其在啤酒澄清中的应用 |
| CN106281935A (zh) * | 2016-08-08 | 2017-01-04 | 山东理工大学 | 一种促进中性蛋白酶活性的方法及其在啤酒澄清中的应用 |
| CN107903208B (zh) * | 2016-12-26 | 2021-09-03 | 杭州市西溪医院 | 一类联芳吡啶类去泛素化酶抑制剂、其制备方法及应用 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| CN111225914B (zh) | 2017-07-24 | 2022-10-11 | 生命医药有限责任公司 | RORγ的抑制剂 |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADATION AND DEGRADATION AGENTS FOR TARGETED PROTEIN DEGRADATION |
| WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| WO2020006269A1 (en) * | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| BR112020026580A2 (pt) | 2018-06-27 | 2021-03-23 | Proteostasis Therapeutics, Inc. (Fem) | Compostos, composição farmacêutica e métodos para tratar um paciente |
| CN120698985A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| EP4090649A4 (en) * | 2020-01-14 | 2024-09-04 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES |
| JP2022012379A (ja) * | 2020-07-01 | 2022-01-17 | 国立大学法人富山大学 | ユビキチン－プロテアソーム系の活性化剤、およびその利用 |
| WO2022250363A1 (ko) * | 2021-05-24 | 2022-12-01 | 재단법인대구경북과학기술원 | 아이유원 계열의 유비퀴틴 특이적 프로테아제 14 억제제를 유효성분으로 포함하는, 프로탁의 항암 효과 증진용 약학적 조성물 |
| WO2025219559A1 (en) * | 2024-04-18 | 2025-10-23 | Booster Therapeutics Gmbh | Pyrrolidine compounds as proteasome stimulators |
| CN119707772B (zh) * | 2024-12-23 | 2025-09-02 | 浙江大学 | 一种usp14共价抑制剂及其制备方法和应用 |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2557341A1 (de) * | 1975-12-19 | 1977-06-30 | Hoechst Ag | Basisch substituierte indolderivate und verfahren zu ihrer herstellung |
| BR8008732A (pt) | 1979-06-28 | 1981-04-28 | Ciba Geigy Ag | Estabilizadores para compostos termoplasticos clorados |
| NL8701682A (nl) | 1986-07-30 | 1988-02-16 | Sandoz Ag | Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten. |
| TW226019B (OSRAM) | 1992-03-23 | 1994-07-01 | Sankyo Co | |
| DE4325204C2 (de) | 1993-07-27 | 2002-11-28 | Matthias Lehr | Acylpyrrolalkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶ |
| US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| EP0639573A1 (de) | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| JPH07133274A (ja) | 1993-11-09 | 1995-05-23 | Sankyo Co Ltd | ピロール誘導体 |
| DE4338770A1 (de) | 1993-11-12 | 1995-05-18 | Matthias Dr Lehr | Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶ |
| ATE229020T1 (de) | 1994-01-19 | 2002-12-15 | Sankyo Co | Pyrrolopyridazin-derivate |
| JPH11501004A (ja) | 1995-02-01 | 1999-01-26 | ユニヴァーシティー・カレッジ・カーディフ・コンサルタンツ・リミテッド | 三環系誘導体及びそれらの抗ガン剤としての使用 |
| US5859035A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| WO1997036881A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| DE19622222A1 (de) | 1996-06-03 | 1997-12-04 | Hoechst Ag | Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide |
| US20040122096A1 (en) | 1996-06-03 | 2004-06-24 | Hoechst Aktiengesellschaft | Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids |
| AU3767997A (en) | 1996-08-01 | 1998-02-25 | Merckle Gmbh | Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2 |
| US5998462A (en) | 1996-12-16 | 1999-12-07 | Allelix Biopharmaceuticals Inc. | 5-alkyl indole compounds |
| EA200000873A1 (ru) | 1998-02-25 | 2001-04-23 | Дженетикс Инститьют, Инк. | Ингибиторы фосфолипазы a |
| US6828344B1 (en) | 1998-02-25 | 2004-12-07 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| US6500853B1 (en) | 1998-02-28 | 2002-12-31 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
| US6867209B1 (en) | 1998-05-22 | 2005-03-15 | Scios, Inc. | Indole-type derivatives as inhibitors of p38 kinase |
| US6589954B1 (en) | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
| AUPP433398A0 (en) | 1998-06-25 | 1998-07-16 | Australian National University, The | Compounds and processes |
| JP2000063354A (ja) | 1998-08-21 | 2000-02-29 | Sumitomo Pharmaceut Co Ltd | ピロール誘導体 |
| JP2001151771A (ja) | 1999-09-10 | 2001-06-05 | Kyowa Hakko Kogyo Co Ltd | 含窒素芳香族複素環誘導体 |
| WO2001044182A2 (en) | 1999-12-16 | 2001-06-21 | Eli Lilly And Company | New synthesis of spla2 inhibitors |
| AR028385A1 (es) | 2000-04-28 | 2003-05-07 | Acadia Pharm Inc | Agonistas muscarinicos |
| ES2172415B2 (es) | 2000-07-28 | 2003-11-16 | Univ Madrid Complutense | Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina. |
| US6951848B2 (en) | 2001-03-12 | 2005-10-04 | Millennium Pharmaceuticals, Inc., | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| EP1453515A4 (en) | 2001-11-09 | 2006-11-29 | Scios Inc | METHOD FOR TREATING CYSTIC FIBROSIS |
| US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| US7632955B2 (en) | 2001-12-13 | 2009-12-15 | National Health Research Institutes | Indole compounds |
| ES2342596T3 (es) | 2002-08-29 | 2010-07-09 | MERCK SHARP & DOHME CORP. | Indoles con actividad anti-diabetica. |
| KR101084871B1 (ko) * | 2003-05-22 | 2011-11-21 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 피라졸로-퀴나졸린 유도체, 그의 제조 방법 및 상기유도체의 키나제 저해제로서의 용도 |
| KR101086654B1 (ko) | 2003-07-15 | 2011-11-24 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규 헤테로아릴 유도체 |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US7767817B2 (en) | 2003-09-05 | 2010-08-03 | Binghe Wang | Water soluble boronic acid fluorescent reporter compounds and methods of use thereof |
| WO2005025515A2 (en) * | 2003-09-12 | 2005-03-24 | California Institute Of Technology | Proteasome pathway inhibitors and related methods |
| TW200522944A (en) | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| EP1773880A4 (en) | 2004-06-08 | 2009-09-09 | Novartis Vaccines & Diagnostic | ENV POLYPEPTIDE COMPLEXES AND METHOD FOR THEIR USE |
| ES2246721B1 (es) | 2004-08-10 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos. |
| US20090264384A1 (en) | 2004-11-01 | 2009-10-22 | Nuada, Inc. | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| JP2008521831A (ja) | 2004-11-30 | 2008-06-26 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| GB0500492D0 (en) | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| US7781479B2 (en) | 2005-01-14 | 2010-08-24 | Dainippon Sumitomo Pharma Co., Ltd. | Heteroaryl derivatives |
| BRPI0607439A2 (pt) | 2005-02-16 | 2010-04-06 | Solvay Pharm Bv | compostos, composição farmacêutica, método de preparação de composições farmacêuticas, e, uso de um composto |
| CA2609980C (en) | 2005-05-27 | 2015-10-13 | Queen's University At Kingston | Treatment of protein folding disorders |
| US20070185184A1 (en) | 2005-09-16 | 2007-08-09 | Serenex, Inc. | Carbazole derivatives |
| EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
| KR20080102181A (ko) | 2006-02-15 | 2008-11-24 | 알러간, 인코포레이티드 | 스핑고신-1-포스페이트 (에스1피) 수용체 길항제 생물학적 활성을 갖는 아릴 또는 헤테로아릴기를 포함하는 인돌-3-카르보실산 아미드, 에스테르, 티오아미드 및 티올 에스테르 화합물 |
| WO2007112322A2 (en) | 2006-03-28 | 2007-10-04 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
| US8877791B2 (en) | 2006-08-04 | 2014-11-04 | Beth Israel Deaconess Medical Center, Inc. | Inhibitors of pyruvate kinase and methods of treating disease |
| AU2007281747B2 (en) | 2006-08-07 | 2013-11-07 | Ironwood Pharmaceuticals, Inc. | Indole compounds |
| WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| EP1902733A1 (en) | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
| US7943659B2 (en) | 2006-10-31 | 2011-05-17 | Takeda Pharmaceutical Company Limited | MAPK/ERK kinase inhibitors |
| US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| WO2008097930A1 (en) | 2007-02-05 | 2008-08-14 | Amira Pharmaceuticals, Inc. | Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors |
| MX2009008439A (es) | 2007-02-12 | 2009-08-13 | Intermune Inc | Nuevos inhibidores de la replicacion del virus de hepatitis c. |
| AU2008222812B2 (en) | 2007-03-08 | 2012-03-22 | Irm Llc | Compounds and compositions as modulators of GPR119 activity |
| CN101016294A (zh) | 2007-03-13 | 2007-08-15 | 中国人民武装警察部队医学院 | 具有多种生物活性的取代吲哚－3－基草酰胺衍生物 |
| CA2681979A1 (en) | 2007-03-29 | 2008-10-09 | Asubio Pharma Co., Ltd. | Indole derivatives having cpla2 inhibiting activity and applications and production methods of the same |
| US8091582B2 (en) | 2007-04-13 | 2012-01-10 | Cla-Val Co. | System and method for hydraulically managing fluid pressure downstream from a main valve between set points |
| WO2008133867A1 (en) | 2007-04-26 | 2008-11-06 | Merck & Co., Inc. | 2-substituted indole derivatives as calcium channel blockers |
| WO2008141013A1 (en) | 2007-05-08 | 2008-11-20 | Allergan, Inc. | S1p3 receptor inhibitors for treating pain |
| WO2008147536A1 (en) * | 2007-05-24 | 2008-12-04 | President And Fellows For Harvard College | Methods and compositions for enhancing proteasome activity |
| US20090118503A1 (en) | 2007-06-20 | 2009-05-07 | Kevin Sprott | Faah inhibitors |
| EP2018861A1 (en) | 2007-07-26 | 2009-01-28 | Laboratorios del Dr. Esteve S.A. | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain |
| ES2358288T3 (es) | 2007-08-01 | 2011-05-09 | Laboratorios Del Dr. Esteve S.A. | Combinación de al menos dos ligandos de 5ht6. |
| EP2217239A2 (en) | 2007-11-07 | 2010-08-18 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| PT2227467E (pt) | 2007-12-04 | 2015-03-02 | Hoffmann La Roche | Derivados de isoxazol-piridina |
| GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
| JP2009179589A (ja) | 2008-01-30 | 2009-08-13 | Pharma Ip | 抗ウイルス剤 |
| WO2009097141A1 (en) | 2008-01-31 | 2009-08-06 | Joslin Diabetes Center | Methods for treatment of kallikrein-related disorders |
| WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| MX2010008198A (es) | 2008-02-25 | 2010-08-23 | Hoffmann La Roche | Inhibidores de cinasa de pirrolopirazina. |
| AU2009225747A1 (en) | 2008-03-17 | 2009-09-24 | Allergan, Inc. | S1P3 receptor inhibitors for treating inflammation |
| WO2009117676A2 (en) | 2008-03-20 | 2009-09-24 | Forest Laboratories Holdings Limited | Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase |
| MX2010010525A (es) * | 2008-03-24 | 2010-10-25 | Novartis Ag | Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida. |
| WO2009121033A2 (en) | 2008-03-27 | 2009-10-01 | University Of Southern California | Substituted nitrogen heterocycles and synthesis and uses thereof |
| RU2492164C2 (ru) | 2008-04-16 | 2013-09-10 | Каро Био Аб | Новые лиганды эстрогеновых рецепторов |
| ES2535516T3 (es) | 2008-04-24 | 2015-05-12 | F2G Limited | Agentes antifúngicos de pirrol |
| GB0808282D0 (en) | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
| EP2306825A4 (en) | 2008-06-26 | 2011-12-28 | Glaxosmithkline Llc | HAMMER OF ACT ACTIVITY |
| JP2011525915A (ja) | 2008-06-26 | 2011-09-29 | アムジエン・インコーポレーテツド | キナーゼ阻害薬としてのアルキニルアルコール類 |
| EP2141163A1 (de) | 2008-07-02 | 2010-01-06 | Bayer Schering Pharma AG | Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| WO2010015816A2 (en) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| JP2011530602A (ja) | 2008-08-12 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｎ−ヘテロ環式ｍ１受容体ポジティブアロステリックモジュレーター |
| US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| US8071605B2 (en) | 2008-12-12 | 2011-12-06 | Astrazeneca Ab | Piperidine compounds for use in the treatment of bacterial infections |
| AU2010226829A1 (en) | 2009-03-18 | 2011-09-15 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| WO2010129553A1 (en) | 2009-05-05 | 2010-11-11 | Allergan, Inc. | S1p3 receptor inhibitors for treating conditions of the eye |
| WO2011019738A1 (en) | 2009-08-10 | 2011-02-17 | Galenea Corporation | Compounds and methods of use thereof |
| CN102216300B (zh) | 2009-09-30 | 2014-10-22 | 贝达药业股份有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| NZ622713A (en) | 2009-10-19 | 2015-07-31 | Synta Pharmaceuticals Corp | Combination cancer therapy with hsp90 inhibitory compounds |
| KR20120117905A (ko) | 2010-01-28 | 2012-10-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 프로테아좀 활성을 향상시키는 조성물 및 방법 |
| US8785490B2 (en) | 2010-04-09 | 2014-07-22 | University Of Louisville Research Foundation, Inc. | Compounds for treating disease, for administering, and for pharmaceutical compositions |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| WO2011133521A2 (en) | 2010-04-19 | 2011-10-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
| EP2575810A1 (en) | 2010-05-24 | 2013-04-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor |
| WO2012012712A2 (en) * | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Tricyclic proteasome activity enhancing compounds |
| CA2810254A1 (en) | 2010-09-13 | 2012-03-22 | Vojo Vukovic | Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients |
| US20140005145A1 (en) | 2010-12-08 | 2014-01-02 | Synta Pharmaceuticals Corp. | Combination breast cancer therapy with hsp90 inhibitory compounds |
| WO2012096919A1 (en) | 2011-01-11 | 2012-07-19 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
| WO2012106343A2 (en) | 2011-02-01 | 2012-08-09 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| WO2012116061A1 (en) | 2011-02-23 | 2012-08-30 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with radiotherapy |
| CN103391779A (zh) | 2011-02-24 | 2013-11-13 | 辛塔医药品有限公司 | 使用hsp90抑制性化合物的前列腺癌治疗 |
| US20140045908A1 (en) | 2011-02-25 | 2014-02-13 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
| PT2707101T (pt) | 2011-05-12 | 2019-05-30 | Proteostasis Therapeutics Inc | Reguladores da proteostase |
| US20140228418A1 (en) | 2011-05-23 | 2014-08-14 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
| EP2714038A1 (en) | 2011-05-24 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors |
| US20140194388A1 (en) | 2011-05-26 | 2014-07-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
| WO2012166415A1 (en) | 2011-05-27 | 2012-12-06 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| WO2013006864A2 (en) | 2011-07-07 | 2013-01-10 | Synta Pharmaceuticals Corp. | Treating cancer with hsp90 inhibitory compounds |
| ES2461997T3 (es) | 2011-07-22 | 2014-05-22 | Université Joseph Fourier | Derivados bis-indólicos nuevos, sus usos, en particular como antibacterianos |
| CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2013067165A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
| WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
-
2011
- 2011-01-28 KR KR1020127022300A patent/KR20120117905A/ko not_active Ceased
- 2011-01-28 CN CN201180016116.9A patent/CN102844313B/zh not_active Expired - Fee Related
- 2011-01-28 MX MX2012008626A patent/MX336731B/es unknown
- 2011-01-28 EP EP11737731.7A patent/EP2528911B1/en not_active Not-in-force
- 2011-01-28 BR BR112012018631A patent/BR112012018631A8/pt not_active Application Discontinuation
- 2011-01-28 WO PCT/US2011/022929 patent/WO2011094545A2/en not_active Ceased
- 2011-01-28 AU AU2011210765A patent/AU2011210765A1/en not_active Abandoned
- 2011-01-28 SG SG2012054235A patent/SG182662A1/en unknown
- 2011-01-28 CA CA2787785A patent/CA2787785C/en not_active Expired - Fee Related
- 2011-01-28 JP JP2012551323A patent/JP2013518129A/ja active Pending
- 2011-01-28 US US13/575,812 patent/US20130045992A1/en not_active Abandoned
- 2011-01-28 RU RU2012136451/04A patent/RU2012136451A/ru not_active Application Discontinuation
-
2015
- 2015-11-05 US US14/933,671 patent/US10351568B2/en not_active Expired - Fee Related
-
2016
- 2016-03-24 JP JP2016060063A patent/JP6371786B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016147893A5 (OSRAM) | ||
| JP2019034943A5 (OSRAM) | ||
| JP2006501295A5 (OSRAM) | ||
| JP2017505779A5 (OSRAM) | ||
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| JP2013532662A5 (OSRAM) | ||
| CA2404125A1 (en) | Sulphonamido-substituted bridged bicycloalkyl derivatives | |
| JP2015531769A5 (OSRAM) | ||
| FI3759088T3 (fi) | Triatsiinijohdannaiset neurotrofiineihin liittyvien sairauksien hoitamiseksi | |
| JP2018504393A5 (OSRAM) | ||
| HRP20180199T1 (hr) | Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1) | |
| CA2718383A1 (en) | Heteroaryl-substituted dicyanopyridines and use thereof for treatment of cardiovascular diseases | |
| JP2019510787A5 (OSRAM) | ||
| IL273000B2 (en) | Compounds that inhibit lysophosphatidic acid receptor 1 (lpar1) | |
| NZ601866A (en) | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | |
| JP2010523623A5 (OSRAM) | ||
| JP2005539026A5 (OSRAM) | ||
| PH12023553013A1 (en) | Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors | |
| JP2020512981A5 (OSRAM) | ||
| JP2006513221A5 (OSRAM) | ||
| JP2013542267A5 (OSRAM) | ||
| JP2010522711A5 (OSRAM) | ||
| PT1513835E (pt) | Derivados de 1-piperazinilacilpiperidina, sua preparação e sua aplicação em terapêutica | |
| JP2004525183A5 (OSRAM) | ||
| ES2749657T3 (es) | Derivados de O-alquil-bencilidenguanidina y su uso terapéutico para el tratamiento de trastornos asociados a una acumulación de proteínas mal plegadas |